| 0.8242 0.053 (6.89%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.24 | 1-year : | 1.47 |
| Resists | First : | 1.06 | Second : | 1.25 |
| Pivot price | 0.84  |
|||
| Supports | First : | 0.75 | Second : | 0.62 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.88 |
| MA(100) : | 1.05 |
MA(250) : | 1.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19 |
D(3) : | 12.3 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 2.28 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCDA ] has closed above bottom band by 38.4%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.83 - 0.83 | 0.83 - 0.84 |
| Low: | 0.78 - 0.78 | 0.78 - 0.79 |
| Close: | 0.81 - 0.82 | 0.82 - 0.83 |
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Thu, 30 Jul 2026
BioCardia Inc (BCDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 29 Jul 2026
BioCardia (NASDAQ: BCDA) CEO buys 5,000 shares at $0.78 - Stock Titan
Wed, 29 Jul 2026
BCDA|BioCardia Inc|Price:0.778|Chg%:+0.004 - TradingKey
Wed, 29 Jul 2026
BioCardia Inc (BCDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 28 Jul 2026
BCDA|BioCardia Inc|Price:0.795|Chg%:-0.013 - TradingKey
Mon, 20 Jul 2026
BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 23.5 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 439 (K) |
| EPS | -0.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -252 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.32 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | -8.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|